Focused On-demand Library for KH domain-containing, RNA-binding, signal transduction-associated protein 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O75525

UPID:

KHDR3_HUMAN

Alternative names:

RNA-binding protein T-Star; Sam68-like mammalian protein 2; Sam68-like phosphotyrosine protein

Alternative UPACC:

O75525; Q6NUL8; Q9UPA8

Background:

KH domain-containing, RNA-binding, signal transduction-associated protein 3, also known as RNA-binding protein T-Star, Sam68-like mammalian protein 2, and Sam68-like phosphotyrosine protein, plays a pivotal role in the regulation of alternative splicing. It influences mRNA splice site selection and exon inclusion, with a preference for the 5'-[AU]UAAA-3' motif. This protein's RNA-binding abilities are modulated by tyrosine kinase PTK6, affecting splice site selection of key growth factors and regulating CD44 alternative splicing. It also plays a role in the neuronal glutamatergic synapse function and plasticity through targeted splicing regulation of NRXN1.

Therapeutic significance:

Understanding the role of KH domain-containing, RNA-binding, signal transduction-associated protein 3 could open doors to potential therapeutic strategies.